194 related articles for article (PubMed ID: 17825982)
41. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lacouture ME; Wu S; Robert C; Atkins MB; Kong HH; Guitart J; Garbe C; Hauschild A; Puzanov I; Alexandrescu DT; Anderson RT; Wood L; Dutcher JP
Oncologist; 2008 Sep; 13(9):1001-11. PubMed ID: 18779536
[TBL] [Abstract][Full Text] [Related]
42. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
43. Risk of arterial thrombosis not increased by sorafenib or sunitinib.
Minor DR
J Clin Oncol; 2010 Oct; 28(30):e619; author reply e620. PubMed ID: 20733133
[No Abstract] [Full Text] [Related]
44. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
Thyroid; 2009 May; 19(5):539-40. PubMed ID: 19416001
[No Abstract] [Full Text] [Related]
45. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
46. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
[TBL] [Abstract][Full Text] [Related]
47. Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study.
Mulder SF; Bertens D; Desar IM; Vissers KC; Mulders PF; Punt CJ; van Spronsen DJ; Langenhuijsen JF; Kessels RP; van Herpen CM
BMC Cancer; 2014 Mar; 14():219. PubMed ID: 24661373
[TBL] [Abstract][Full Text] [Related]
48. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
49. Reversible cardiomyopathy associated with sunitinib and sorafenib.
Uraizee I; Cheng S; Moslehi J
N Engl J Med; 2011 Oct; 365(17):1649-50. PubMed ID: 22030001
[No Abstract] [Full Text] [Related]
50. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
Lenihan DJ
J Clin Oncol; 2008 Nov; 26(32):5154-5. PubMed ID: 18838702
[No Abstract] [Full Text] [Related]
51. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
Dasanu CA; Alexandrescu DT; Dutcher J
South Med J; 2007 Mar; 100(3):328-30. PubMed ID: 17396743
[TBL] [Abstract][Full Text] [Related]
52. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Coriat R; Ropert S; Mir O; Billemont B; Chaussade S; Massault PP; Blanchet B; Vignaux O; Goldwasser F
Invest New Drugs; 2011 Oct; 29(5):1090-3. PubMed ID: 20524036
[TBL] [Abstract][Full Text] [Related]
53. Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma.
Lamarca A; Feliu J; Barriuso J
Br J Cancer; 2012 Mar; 106(6):1246. PubMed ID: 22294185
[No Abstract] [Full Text] [Related]
54. Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib.
Chung C; Dawson LA; Joshua AM; Brade AM
Anticancer Drugs; 2010 Feb; 21(2):206-9. PubMed ID: 19952730
[TBL] [Abstract][Full Text] [Related]
55. Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
Turan N; Benekli M; Ozturk SC; Inal S; Memis L; Guz G; Cetin B; Buyukberber S
Ann Pharmacother; 2012 Oct; 46(10):e27. PubMed ID: 23032654
[TBL] [Abstract][Full Text] [Related]
56. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
57. Sorafenib: muscle wasting.
Prescrire Int; 2011 Dec; 20(122):296-7. PubMed ID: 22216546
[TBL] [Abstract][Full Text] [Related]
58. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Pouessel D; Culine S
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
[TBL] [Abstract][Full Text] [Related]
59. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
Nat Rev Clin Oncol; 2009 Apr; 6(4):219-28. PubMed ID: 19333228
[TBL] [Abstract][Full Text] [Related]
60. Risk of bleeding not increased by sorafenib or sunitinib.
Minor DR
Lancet Oncol; 2010 Feb; 11(2):112-3; author reply 113. PubMed ID: 20152763
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
